CEPI teams up with Ko­re­an vac­cine mak­er in $140M pact to scale up its nascent mR­NA plat­form

Just a month af­ter ship­ping out the ini­tial batch of its home­grown nanopar­ti­cle Covid-19 vac­cines, South Ko­rea’s SK bio­science has signed a deal with the Coali­tion for Epi­dem­ic Pre­pared­ness In­no­va­tions to try out a dif­fer­ent tech­nol­o­gy plat­form: mR­NA.

CEPI is of­fer­ing the com­pa­ny up to $40 mil­lion for ear­ly de­vel­op­ment of an mR­NA vac­cine plat­form, in­clud­ing two ini­tial projects, with an­oth­er $100 mil­lion on the line if it moves in­to late-stage tri­als.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER